Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy.

Frontiers in immunology - 1 Jan 2021

Lee Jongdae, Lozano-Ruiz Beatriz, Yang Fengyuan Mandy, Fan Dengxia Denise, Shen Liya, González-Navajas Jose M

Abstract excerpt

During the last decade, immune checkpoint inhibition (ICI) has become a pillar of cancer therapy. Antibodies targeting CTLA-4 or PD-1/PD-L1 have been approved in several malignancies, with thousands of clinical trials currently underway. While the majority of cancer immunotherapies have traditionally focused on enhancing cytotoxic responses by CD8+ or NK cells, there are clear evidences that CD4+ T cell responses...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune Checkpoint Inhibitors
Share to Lymphocytes, Tumor-Infiltrating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Phenotype

Share to Th1 Cells

Share to Th17 Cells

Share to Treatment Outcome

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 33777008
DOI: 10.3389/fimmu.2021.625667
PMCID: PMC7994325

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy.PMID 33777008Read ↗

Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity Read ↗

T lymphocyte subsets in cancer immunity: Friends or foesSemantic proximity Read ↗

Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy.Semantic proximity Read ↗

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer TherapeuticsSemantic proximity Read ↗

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious DiseasesSemantic proximity Read ↗

Tumor immune checkpoints and their associated inhibitorsSemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

The outstanding antitumor capacity of CD4+ T helper lymphocytesSemantic proximity Read ↗

PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity.Semantic proximity Read ↗

Immunological Classification of Tumor Types and Advances in Precision Combination Immunotherapy.Semantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

Advances in cancer immunotherapy: historical perspectives, current developments, and future directionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.